Local, but not circulating, complement C3 governs immune checkpoint blockade efficacy
Miyai, Y.; Shiraki, Y.; Sugiyama, D.; Sato, Y.; Kato, K.; Asai, N.; Cao, F.; Nagao, N.; Tanabe, K.; Nakatochi, M.; Hase, T.; Yoshikawa, T. F. C.; Kobayashi, T.; Iwama, S.; Esaki, N.; Mii, S.; Arima, H.; Kimura, H.; Takahashi, M.; Ando, Y.; Enomoto, A.
Show abstract
The roles of circulating complement C3, produced in hepatocytes, in immune defense are well defined in the literature. Interestingly, the C3 gene evolved before the circulatory system, suggesting an essential but yet unknown role of locally produced C3. Here, we investigated the effect of C3 on cancer immunotherapy and found that cancer-associated fibroblast (CAF)-derived C3, not hepatocyte-derived C3, determines the efficacy of immune checkpoint blockade (ICB). Tumors developed in CAF-specific C3 knockout mice exhibited resistance to anti-PD-1 therapy, with increased immunosuppressive M2-like macrophage infiltration. Mechanistically, the C3 degradation product iC3b suppressed myeloid cell infiltration via complement receptor 3 signaling, and the therapeutic targeting of this pathway restored ICB sensitivity of immunotherapy-resistant tumors. In human cancers, stromal C3 expression correlates with reduced M2-like macrophage infiltration and improved immunotherapeutic outcomes. These data demonstrate the role of locally produced C3 in the innate immune response, which may have been conserved across many organisms.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 98%
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 97%
- Combinatorial immunotherapies overcome MYC-driven immune evasion 97%
Similar papers in this journal
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 96%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 96%
- Cell lineage as a predictor of immune response in neuroblastoma 96%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 97%
- B3GALT6 Promotes Dormant Breast Cancer Cell Survival and Recurrence by Enabling Heparan Sulfate-Mediated FGF Signaling 97%
- Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.